BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dong D, Gao X, Zhu Z, Yu Q, Bian S, Gao Y. A 40-bp insertion/deletion polymorphism in the constitutive promoter of MDM2 confers risk for hepatocellular carcinoma in a Chinese population. Gene. 2012;497:66-70. [PMID: 22285926 DOI: 10.1016/j.gene.2012.01.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Andrade RB, Cavalcante GC, Amador MAT, Moreira FC, Khayat AS, Assumpção PP, Ribeiro-dos-santos Â, Santos NPC, Santos S. The Search for Cancer Biomarkers: Assessing the Distribution of INDEL Markers in Different Genetic Ancestries. CIMB 2022;44:2275-86. [DOI: 10.3390/cimb44050154] [Reference Citation Analysis]
2 Timóteo M, Tavares A, Cruz S, Campos C, Medeiros R, Sousa H. Association of Murine Double Minute 2 polymorphisms with gastric cancer: A systematic review with meta-analysis. Biomed Rep 2021;15:69. [PMID: 34257965 DOI: 10.3892/br.2021.1445] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Gansmo LB, Lie BA, Mæhlen MT, Vatten L, Romundstad P, Hveem K, Lønning PE, Knappskog S. Polymorphisms in the TP53-MDM2-MDM4-axis in patients with rheumatoid arthritis. Gene 2021;793:145747. [PMID: 34077778 DOI: 10.1016/j.gene.2021.145747] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Klein AM, de Queiroz RM, Venkatesh D, Prives C. The roles and regulation of MDM2 and MDMX: it is not just about p53. Genes Dev 2021;35:575-601. [PMID: 33888565 DOI: 10.1101/gad.347872.120] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Miedl H, Dietrich B, Kaserer K, Schreiber M. The 40bp Indel Polymorphism rs150550023 in the MDM2 Promoter is Associated with Intriguing Shifts in Gene Expression in the p53-MDM2 Regulatory Hub. Cancers (Basel) 2020;12:E3363. [PMID: 33202864 DOI: 10.3390/cancers12113363] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Jalilvand A, Yari K, Aznab M, Rahimi Z, Salahshouri Far I, Mohammadi P. A case-control study on the SNP309T → G and 40-bp Del1518 of the MDM2 gene and a systematic review for MDM2 polymorphisms in the patients with breast cancer. J Clin Lab Anal 2020;34:e23529. [PMID: 32951271 DOI: 10.1002/jcla.23529] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Tripon F, Iancu M, Trifa A, Crauciuc GA, Boglis A, Balla B, Cosma A, Dima D, Candea M, Lazar E, Jimbu L, Banescu C. Association Analysis of TP53 rs1042522, MDM2 rs2279744, rs3730485, MDM4 rs4245739 Variants and Acute Myeloid Leukemia Susceptibility, Risk Stratification Scores, and Clinical Features: An Exploratory Study. J Clin Med 2020;9:E1672. [PMID: 32492903 DOI: 10.3390/jcm9061672] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Yi X, Zhou Q, Sui G, Ren G, Tan L, Li J, Lin J, Bao S. Interactions among variants in P53 apoptotic pathway genes are associated with neurologic deterioration and functional outcome after acute ischemic stroke. Brain Behav 2021;11:e01492. [PMID: 31909567 DOI: 10.1002/brb3.1492] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Yari K, Jalilvand A. Comment on: 'A 40-bp insertion/deletion polymorphism in the constitutive promoter of MDM2 confers risk for hepatocellular carcinoma in a Chinese population'. Gene 2019;712:143965. [PMID: 31279708 DOI: 10.1016/j.gene.2019.143965] [Reference Citation Analysis]
10 Maruei-Milan R, Heidari Z, Salimi S. Role of MDM2 309T>G (rs2279744) and I/D (rs3730485) polymorphisms and haplotypes in risk of papillary thyroid carcinoma, tumor stage, tumor size, and early onset of tumor: A case control study. J Cell Physiol 2019;234:12934-40. [PMID: 30548972 DOI: 10.1002/jcp.27960] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
11 Duan X, Yang Y, Wang S, Feng X, Wang T, Wang P, Yao W, Cui L, Wang W. Interaction between polymorphisms in cell-cycle genes and environmental factors in regulating cholinesterase activity in people with exposure to omethoate. R Soc Open Sci 2018;5:172357. [PMID: 29892419 DOI: 10.1098/rsos.172357] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
12 Cavalcante GC, Amador MA, Ribeiro dos Santos AM, Carvalho DC, Andrade RB, Pereira EE, Fernandes MR, Costa DF, Santos NP, Assumpção PP, Ribeiro dos Santos Â, Santos S. Analysis of 12 variants in the development of gastric and colorectal cancers. World J Gastroenterol 2017; 23(48): 8533-8543 [PMID: 29358861 DOI: 10.3748/wjg.v23.i48.8533] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
13 Gansmo LB, Vatten L, Romundstad P, Hveem K, Ryan BM, Harris CC, Knappskog S, Lønning PE. Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate. Oncotarget 2016;7:28637-46. [PMID: 27081698 DOI: 10.18632/oncotarget.8705] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
14 Hua W, Zhang A, Duan P, Zhu J, Zhao Y, He J, Zhang Z. MDM2 promoter del1518 polymorphism and cancer risk: evidence from 22,931 subjects. Onco Targets Ther 2017;10:3773-80. [PMID: 28794641 DOI: 10.2147/OTT.S140424] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
15 Duan X, Yang Y, Wang S, Feng X, Wang T, Wang P, Liu S, Li L, Yao W, Cui L, Wang W. Changes in the expression of genes involved in cell cycle regulation and the relative telomere length in the process of canceration induced by omethoate. Tumour Biol 2017;39:1010428317719782. [PMID: 28718371 DOI: 10.1177/1010428317719782] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
16 Hashemi M, Amininia S, Ebrahimi M, Simforoosh N, Basiri A, Ziaee SAM, Narouie B, Sotoudeh M, Mollakouchekian MJ, Rezghi Maleki E. Association between polymorphisms in TP53 and MDM2 genes and susceptibility to prostate cancer. Oncol Lett. 2017;13:2483-2489. [PMID: 28454424 DOI: 10.3892/ol.2017.5739] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
17 Gansmo LB, Bjørnslett M, Halle MK, Salvesen HB, Romundstad P, Hveem K, Vatten L, Dørum A, Lønning PE, Knappskog S. MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk. BMC Cancer 2017;17:97. [PMID: 28158999 DOI: 10.1186/s12885-017-3094-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
18 Hashemi M, Omrani M, Eskandari-Nasab E, Hasani SS, Mashhadi MA, Taheri M. A 40-bp insertion/deletion polymorphism of Murine Double Minute2 (MDM2) increased the risk of breast cancer in Zahedan, Southeast Iran. Iran Biomed J 2014;18:245-9. [PMID: 25326024 DOI: 10.6091/ibj.13332.2014] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
19 Qian J, Liu H, Gu S, Wu Q, Zhao X, Wu W, Wang H, Wang J, Chen H, Zhang W, Wei Q, Jin L, Lu D. Genetic Variants of the MDM2 Gene Are Predictive of Treatment-Related Toxicities and Overall Survival in Patients With Advanced NSCLC. Clin Lung Cancer 2015;16:e37-53. [PMID: 25818095 DOI: 10.1016/j.cllc.2015.02.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
20 Liu M, Zheng SJ, Chen Y, Li N, Ren PF, Dai LP, Duan ZP, Zhang JY. Autoantibody response to murine double minute 2 protein in immunodiagnosis of hepatocellular carcinoma. J Immunol Res. 2014;2014:906532. [PMID: 24955377 DOI: 10.1155/2014/906532] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
21 Sanchez R, St-Cyr J, Lalonde ME, Healy J, Richer C, Gagné V, Laverdière C, Silverman LB, Sallan SE, Neuberg D, Kutok JL, Kritikou EA, Krajinovic M, Sinnett D. Impact of promoter polymorphisms in key regulators of the intrinsic apoptosis pathway on the outcome of childhood acute lymphoblastic leukemia. Haematologica 2014;99:314-21. [PMID: 24038028 DOI: 10.3324/haematol.2013.085340] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
22 Chen J, Ma L, Peng NF, Wang SJ, Li LQ. A meta-analysis of the relationship between glutathione S-transferases gene polymorphism and hepatocellular carcinoma in Asian population. Mol Biol Rep. 2012;39:10383-10393. [PMID: 23053942 DOI: 10.1007/s11033-012-1917-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
23 Moazeni-Roodi A, Ghavami S, Hashemi M. The 40bp indel polymorphism of MDM2 increase the risk of cancer: An updated meta-analysis. Mol Biol Res Commun 2019;8:1-8. [PMID: 31528638 DOI: 10.22099/mbrc.2019.31527.1364] [Cited by in F6Publishing: 2] [Reference Citation Analysis]